Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma patients

The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant. Researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF.